Revolution Medicines Develops Promising New Pill for Pancreatic Cancer Treatment
Revolution Medicines has developed a new drug, daraxonrasib, targeting the KRAS gene mutation prevalent in pancreatic cancer patients. The drug has shown promising results in clinical trials, nearly doubling the survival rate of patients compared to standard chemotherapy. The pill is part of a class of drugs known as RAS inhibitors and has been tested on patients with pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer. The trial results indicate that the drug could significantly improve treatment outcomes for this deadly cancer, which has a low five-year survival rate. The drug has been fast-tracked for limited approval by the FDA, although it is not yet widely available. 
